Back to Search Start Over

A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase.

Authors :
Monovich L
Vega RB
Meredith E
Miranda K
Rao C
Capparelli M
Lemon DD
Phan D
Koch KA
Chapo JA
Hood DB
McKinsey TA
Source :
FEBS letters [FEBS Lett] 2010 Feb 05; Vol. 584 (3), pp. 631-7. Date of Electronic Publication: 2009 Dec 14.
Publication Year :
2010

Abstract

Class IIa histone deacetylases (HDACs) repress genes involved in pathological cardiac hypertrophy. The anti-hypertrophic action of class IIa HDACs is overcome by signals that promote their phosphorylation-dependent nuclear export. Several kinases have been shown to phosphorylate class IIa HDACs, including calcium/calmodulin-dependent protein kinase (CaMK), protein kinase D (PKD) and G protein-coupled receptor kinase (GRK). However, the identity of the kinase(s) responsible for phosphorylating class IIa HDACs during cardiac hypertrophy has remained controversial. We describe a novel and selective small molecule inhibitor of PKD, bipyridyl PKD inhibitor (BPKDi). BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes and concomitantly suppresses hypertrophy of these cells. These studies define PKD as a principal cardiac class IIa HDAC kinase.<br /> (2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-3468
Volume :
584
Issue :
3
Database :
MEDLINE
Journal :
FEBS letters
Publication Type :
Academic Journal
Accession number :
20018189
Full Text :
https://doi.org/10.1016/j.febslet.2009.12.014